Becker's Healthcare May 10, 2022
Pfizer has agreed to acquire the migraine treatment maker Biohaven Pharmaceuticals for $11.6 billion, the drugmaker said May 10.
Four things to know:
1. Pfizer first invested in Biohaven last November, according to ABC News. The company will buy all remaining shares at $148.50 per share in cash.
2. Biohaven makes rimegepant, an FDA-approved...